Graphite Bio, Inc.

201 Haskins Way, Suite 210

South San Francisco, CA 94080

July 26, 2022

Via EDGAR Transmission

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Re: Graphite Bio, Inc.: Registration Statement on Form S-3 filed July 21, 2022 (File No. 333-266262)

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Graphite Bio, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to July 28, 2022, at 4:00 pm Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

If you have any questions regarding this request, please contact Maggie Wong of Goodwin Procter LLP at (415) 733-6071.



Graphite Bio, Inc.

/s/ Alethia Young

Alethia Young

Chief Financial Officer



Josh Lehrer, Graphite Bio, Inc.

Mitchell Bloom, Goodwin Procter LLP

Maggie Wong, Goodwin Procter LLP

Shoaib Ghias, Goodwin Procter LLP